Pacific Biosciences of California 

$2.17
0
-$0.15-6.47% Today

Statistics

Day High
2.24
Day Low
2.1
52W High
-
52W Low
-
Volume
324,182
Avg. Volume
-
Mkt Cap
655.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12FebExpected
Q3 2025
Next
-0.15
-0.14
-0.14
-0.13
Expected EPS
-0.143696
Actual EPS
N/A

Financials

-201.18%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
308.03MRevenue
-619.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PACB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina offers sequencing and array-based solutions for genetic and genomic analysis, directly competing in the DNA sequencing market with PACB.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics provides optical genome mapping solutions, which compete with PACB's long-read sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a range of sequencing and genetic analysis products, competing in the broader genomics space with PACB.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen offers sample to insight solutions including sequencing technologies that compete with PACB's offerings.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR gene editing, a field that relies on accurate DNA sequencing, where PACB's technologies are used.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing space, competing indirectly by relying on sequencing technologies similar to those offered by PACB for its gene editing projects.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene-based medicine, depending on sequencing technologies where PACB's long-read capabilities are beneficial.
Agenus
AGEN
Mkt Cap126.5M
Agenus is involved in immuno-oncology, a field that increasingly relies on genomic sequencing for personalized medicine, indirectly competing with PACB.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health focuses on liquid biopsies and cancer diagnostics, using sequencing technologies that compete with PACB's offerings in the genomic analysis market.

About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Show more...
CEO
Mr. Christian O. Henry M.B.A.
Employees
575
Country
US
ISIN
US69404D1081

Listings

0 Comments

Share your thoughts

FAQ

What is Pacific Biosciences of California stock price today?
The current price of PACB.BOATS is $2.17 USD — it has decreased by -6.47% in the past 24 hours. Watch Pacific Biosciences of California stock price performance more closely on the chart.
What is Pacific Biosciences of California stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pacific Biosciences of California stocks are traded under the ticker PACB.BOATS.
What is Pacific Biosciences of California market cap?
Today Pacific Biosciences of California has the market capitalization of 655.14M
When is the next Pacific Biosciences of California earnings date?
Pacific Biosciences of California is going to release the next earnings report on February 12, 2026.
What were Pacific Biosciences of California earnings last quarter?
PACB.BOATS earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.15 USD resulting in a +14.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pacific Biosciences of California revenue for the last year?
Pacific Biosciences of California revenue for the last year amounts to 308.03M USD.
What is Pacific Biosciences of California net income for the last year?
PACB.BOATS net income for the last year is -619.7M USD.
How many employees does Pacific Biosciences of California have?
As of February 02, 2026, the company has 575 employees.
In which sector is Pacific Biosciences of California located?
Pacific Biosciences of California operates in the Health Care sector.
When did Pacific Biosciences of California complete a stock split?
Pacific Biosciences of California has not had any recent stock splits.
Where is Pacific Biosciences of California headquartered?
Pacific Biosciences of California is headquartered in Menlo Park, US.